<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130844</url>
  </required_header>
  <id_info>
    <org_study_id>SPD476-112</org_study_id>
    <secondary_id>2011-000164-10</secondary_id>
    <nct_id>NCT01130844</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis</brief_title>
  <official_title>A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and pharmacokinetics of MMX mesalamine
      following administration in children and adolescents with ulcerative colitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of MMX Mesalamine (5-ASA) at Steady State</measure>
    <time_frame>2, 4, 6, 9, 12, 16, and 24 hours post-dose on day 7</time_frame>
    <description>AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of MMX Mesalamine (5-ASA) at Steady State</measure>
    <time_frame>Over a 24-hour period starting on day 7</time_frame>
    <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of MMX Mesalamine (5-ASA) at Steady State</measure>
    <time_frame>Over a 24-hour period starting on day 7</time_frame>
    <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Body Clearance (CL) of MMX Mesalamine (5-ASA) at Steady State</measure>
    <time_frame>Over a 24-hour period starting on day 7</time_frame>
    <description>Clearance of a substance from the blood by the kidneys.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</measure>
    <time_frame>2, 4, 6, 9, 12, 16, and 24 hours post-dose on day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</measure>
    <time_frame>Over a 24-hour period starting on day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</measure>
    <time_frame>Over a 24-hour period starting on day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</measure>
    <time_frame>Over a 24-hour period starting on day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Dose Absorbed For MMX Mesalamine (5-ASA) in Urine at Steady State</measure>
    <time_frame>Over a 24-hour period starting on day 7</time_frame>
    <description>The percentage of the dose absorbed was calculated as: 100 x (Xu0-24h 5-ASA + [0.7847* Xu0-24h Ac-5-ASA])/dose, where 0.7847 is the ratio of the molecular weight of 5-ASA (153.14) to the molecular weight of Ac-5-ASA (195.15). Xu0-24h is equal to the cumulative amount recovered in urine in the time interval of 0 to 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount of MMX Mesalamine (5-ASA) Recovered in Urine at Steady State</measure>
    <time_frame>Over a 24-hour period starting on day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount of MMX Mesalamine Major Metabolite (Ac-5-ASA) Recovered in Urine at Steady State</measure>
    <time_frame>Over a 24-hour period starting on day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>MMX Mesalamine (30mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MMX Mesalamine (60 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MMX Mesalamine (100 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMX Mesalamine</intervention_name>
    <description>30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
    <arm_group_label>MMX Mesalamine (30mg/kg)</arm_group_label>
    <other_name>Lialda, SPD476</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMX Mesalamine</intervention_name>
    <description>60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
    <arm_group_label>MMX Mesalamine (60 mg/kg)</arm_group_label>
    <other_name>Lialda, SPD476</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMX Mesalamine</intervention_name>
    <description>100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
    <arm_group_label>MMX Mesalamine (100 mg/kg)</arm_group_label>
    <other_name>Lialda, SPD476</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged 5-17 years, with appropriately obtained informed consent and assent.

          2. Subject has a documented history of ulcerative colitis for at least 3 months.

          3. Subjects who are currently on 5-ASA or product(s) containing or metabolized to
             mesalamine must have been on a stable regimen for at least 4 weeks prior to first dose
             of investigational medicinal product.

          4. Subjects who are not currently on a drug regimen, or on a 5-ASA or product containing
             or metabolized to mesalamine, must have been on a stable regimen for at least 4 weeks
             prior to first dose at least 4 weeks prior first dose of investigational medicinal
             product.

          5. Body weight of 18kg-82kg inclusive.

        Exclusion Criteria:

          1. Current or recurrent disease (eg cardiovascular, renal, liver, malignancy or other
             conditions) that could affect the colon, the action, absorption or disposition of the
             IMP, or clinical or laboratory assessments with the exception of their existing
             ulcerative colitis.

          2. Ulcerative Colitis known to be confined to the rectum (isolated rectal proctitis).

          3. Any history of hepatic impairment or moderate to severe renal impairment.

          4. The use of systemic or rectal steroids within the last 4 weeks, immunomodulators
             within the last 6 weeks, biologics within 6 months, antibiotic use within the last 7
             days prior to the first dose of investigational medicinal product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center for Children</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Pediatrii Gastroenterologii i Zywienia, Uniwersytecki Szpital Dzieciecy w Krakowie</name>
      <address>
        <city>Wieliczka</city>
        <state>Krakow</state>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Pediatrii Dzieciecy Szpital Kliniczny im prof Antoniego Gebali</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniczny Oddzial Pediatrii z Pododdzialem Neurologii Dzieciecej Szpital Wojewodzki</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Gastroenterolofii Pediatrii, Instytut Centrum Zdrowia Matki Polki</name>
      <address>
        <city>Rzgowska</city>
        <zip>281/289</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Gastroenterologii i Hepatologii, Instytut Pomnik-Centrum Zdrowia Dziecka</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologicka ambulancia</name>
      <address>
        <city>Limbova 2</city>
        <state>Bratislava</state>
        <zip>824 02</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <state>Kollarova 2</state>
        <zip>036 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFNsP Banska Bystrica</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 09</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust/Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somers Clinical Research Facility/Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <results_first_submitted>May 9, 2014</results_first_submitted>
  <results_first_submitted_qc>June 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2015</results_first_posted>
  <last_update_submitted>June 15, 2015</last_update_submitted>
  <last_update_submitted_qc>June 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MMX Mesalamine (30mg/kg)</title>
          <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>MMX Mesalamine (60 mg/kg)</title>
          <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
        </group>
        <group group_id="P3">
          <title>MMX Mesalamine (100 mg/kg)</title>
          <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MMX Mesalamine (30mg/kg)</title>
          <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>MMX Mesalamine (60 mg/kg)</title>
          <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>MMX Mesalamine (100 mg/kg)</title>
          <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.0" spread="2.88"/>
                    <measurement group_id="B2" value="13.9" spread="2.59"/>
                    <measurement group_id="B3" value="10.6" spread="3.28"/>
                    <measurement group_id="B4" value="13.3" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>5 to 17 years, inclusive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) of MMX Mesalamine (5-ASA) at Steady State</title>
        <description>AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
        <time_frame>2, 4, 6, 9, 12, 16, and 24 hours post-dose on day 7</time_frame>
        <population>The Pharmacokinetic Set (PKS) consisted of all subjects in the Safety Analysis Set who generated sufficient plasma samples to allow reliable determination of Cmax and AUC. The Safety Analysis Set consisted of subjects who took at least 1 dose of investigational product and had at least 1 post-dose safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) of MMX Mesalamine (5-ASA) at Steady State</title>
          <description>AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
          <population>The Pharmacokinetic Set (PKS) consisted of all subjects in the Safety Analysis Set who generated sufficient plasma samples to allow reliable determination of Cmax and AUC. The Safety Analysis Set consisted of subjects who took at least 1 dose of investigational product and had at least 1 post-dose safety assessment.</population>
          <units>ug*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21411" spread="11081"/>
                    <measurement group_id="O2" value="46173" spread="22864"/>
                    <measurement group_id="O3" value="49213" spread="17664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Dose Absorbed For MMX Mesalamine (5-ASA) in Urine at Steady State</title>
        <description>The percentage of the dose absorbed was calculated as: 100 x (Xu0-24h 5-ASA + [0.7847* Xu0-24h Ac-5-ASA])/dose, where 0.7847 is the ratio of the molecular weight of 5-ASA (153.14) to the molecular weight of Ac-5-ASA (195.15). Xu0-24h is equal to the cumulative amount recovered in urine in the time interval of 0 to 24 hours.</description>
        <time_frame>Over a 24-hour period starting on day 7</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Dose Absorbed For MMX Mesalamine (5-ASA) in Urine at Steady State</title>
          <description>The percentage of the dose absorbed was calculated as: 100 x (Xu0-24h 5-ASA + [0.7847* Xu0-24h Ac-5-ASA])/dose, where 0.7847 is the ratio of the molecular weight of 5-ASA (153.14) to the molecular weight of Ac-5-ASA (195.15). Xu0-24h is equal to the cumulative amount recovered in urine in the time interval of 0 to 24 hours.</description>
          <population>PKS</population>
          <units>percentage of dose absorbed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="14.5"/>
                    <measurement group_id="O2" value="27.0" spread="13.5"/>
                    <measurement group_id="O3" value="22.1" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of MMX Mesalamine (5-ASA) at Steady State</title>
        <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
        <time_frame>Over a 24-hour period starting on day 7</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of MMX Mesalamine (5-ASA) at Steady State</title>
          <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
          <population>PKS</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1884" spread="1018"/>
                    <measurement group_id="O2" value="3825" spread="1979"/>
                    <measurement group_id="O3" value="4314" spread="2602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of MMX Mesalamine (5-ASA) at Steady State</title>
        <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
        <time_frame>Over a 24-hour period starting on day 7</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of MMX Mesalamine (5-ASA) at Steady State</title>
          <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
          <population>PKS</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="0.00" upper_limit="24.0"/>
                    <measurement group_id="O2" value="8.98" lower_limit="0.00" upper_limit="24.0"/>
                    <measurement group_id="O3" value="1.98" lower_limit="0.00" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Body Clearance (CL) of MMX Mesalamine (5-ASA) at Steady State</title>
        <description>Clearance of a substance from the blood by the kidneys.</description>
        <time_frame>Over a 24-hour period starting on day 7</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance (CL) of MMX Mesalamine (5-ASA) at Steady State</title>
          <description>Clearance of a substance from the blood by the kidneys.</description>
          <population>PKS</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.48" spread="2.99"/>
                    <measurement group_id="O2" value="5.94" spread="2.95"/>
                    <measurement group_id="O3" value="4.95" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</title>
        <time_frame>2, 4, 6, 9, 12, 16, and 24 hours post-dose on day 7</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine Metabolite (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine Metabolite (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine Metabolite (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</title>
          <population>PKS</population>
          <units>ug*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30942" spread="13743"/>
                    <measurement group_id="O2" value="58119" spread="22729"/>
                    <measurement group_id="O3" value="63067" spread="21752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</title>
        <time_frame>Over a 24-hour period starting on day 7</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine Metabolite (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine Metabolite (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine Metabolite (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</title>
          <population>PKS</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2396" spread="1217"/>
                    <measurement group_id="O2" value="4113" spread="1641"/>
                    <measurement group_id="O3" value="4968" spread="2911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</title>
        <time_frame>Over a 24-hour period starting on day 7</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine Metabolite (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine Metabolite (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine Metabolite (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</title>
          <population>PKS</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" lower_limit="0.00" upper_limit="24.0"/>
                    <measurement group_id="O2" value="7.48" lower_limit="0.00" upper_limit="24.0"/>
                    <measurement group_id="O3" value="1.98" lower_limit="0.00" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</title>
        <time_frame>Over a 24-hour period starting on day 7</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine Metabolite (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine Metabolite (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine Metabolite (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>CL of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State</title>
          <population>PKS</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="6.72"/>
                    <measurement group_id="O2" value="12.2" spread="4.43"/>
                    <measurement group_id="O3" value="10.0" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amount of MMX Mesalamine (5-ASA) Recovered in Urine at Steady State</title>
        <time_frame>Over a 24-hour period starting on day 7</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amount of MMX Mesalamine (5-ASA) Recovered in Urine at Steady State</title>
          <population>PKS</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" spread="132"/>
                    <measurement group_id="O2" value="298" spread="221"/>
                    <measurement group_id="O3" value="235" spread="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amount of MMX Mesalamine Major Metabolite (Ac-5-ASA) Recovered in Urine at Steady State</title>
        <time_frame>Over a 24-hour period starting on day 7</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>MMX Mesalamine Metabolite (30mg/kg)</title>
            <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>MMX Mesalamine Metabolite (60 mg/kg)</title>
            <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>MMX Mesalamine Metabolite (100 mg/kg)</title>
            <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amount of MMX Mesalamine Major Metabolite (Ac-5-ASA) Recovered in Urine at Steady State</title>
          <population>PKS</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532" spread="411"/>
                    <measurement group_id="O2" value="708" spread="341"/>
                    <measurement group_id="O3" value="593" spread="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MMX Mesalamine (30mg/kg)</title>
          <description>MMX Mesalamine: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>MMX Mesalamine (60 mg/kg)</title>
          <description>MMX Mesalamine: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
        </group>
        <group group_id="E3">
          <title>MMX Mesalamine (100 mg/kg)</title>
          <description>MMX Mesalamine: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire Development LLC</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

